Volumetric analysis of mandibular lesions with SPECT/CT: a pilot clinical study of maximum standardized uptake value

Yoshiyuki Minami1B,D, Ruri Ogawa1C,F, Ichiro Ogura1,2,A,E,G

1Quantitative Diagnostic Imaging, Field of Oral and Maxillofacial Imaging and Histopathological Diagnostics, Course of Applied Science, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan
2Department of Oral and Maxillofacial Radiology, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Japan

Abstract

Purpose: This study was designed to investigate mandibular lesions using volumetric analysis with bone single-photon emission computed tomography/computed tomography (SPECT/CT).

Material and methods: Eight patients with mandibular lesions underwent SPECT/CT scan acquisition 4 hours after injection of Tc-99m hydroxymethylene diphosphonate (HMDP). Regarding volumetric analysis, maximum standardized uptake value (SUV) was obtained using software and a workstation (Q.Volumetrix MI and GEniE-Xeleris 4 DR, respectively). The localization and size of the volume of interest (VOI) can be drawn over the lesion, mesial, distal, and opposite side as normal using the CT, SPECT, and SPECT/CT transaxials, coronals, and sagittals as the anatomical reference. Q.Volumetrix MI can analyse SUV of lesions by organ segmentation using optional pan and zoom imaging. Then, the dosimetry software provided multiple quantitative data for a given VOI. Statistical analyses for the maximum SUV were performed by Mann-Whitney U test. A p-value lower than 0.05 was considered as statistically significant.

Results: Maximum SUVs for medication-related osteonecrosis of the jaw (n = 4, 25.4 ± 4.9), chronic osteomyelitis (n = 3, 14.6 ± 3.1), and squamous cell carcinoma (n = 1, 31.7) were significantly higher than those of the opposite side as normal mandible (3.8 ± 0.7, 4.6 ± 1.8, and 7.4, respectively; p = 0.000).

Conclusions: Volumetric analysis with SPECT/CT could be useful for the evaluation of mandibular lesions, such as detecting and surgical planning.

Key words: single photon emission computed tomography, radionuclide imaging, bisphosphonate-associated osteonecrosis of the jaw.

Introduction

Single-photon emission computed tomography/computed tomography (SPECT/CT) plays an important role in assessing oral and maxillofacial lesions [1-4]. SPECT/CT is useful not only for detecting jaw bone invasion of oral cancer but also for surgical planning [5]. Furthermore, radiologic-pathologic correlation of medication-related osteonecrosis of the jaw (MRONJ) could be achieved using SPECT/CT [6].

SPECT/CT can provide the quantitative parameter standardized uptake value (SUV) [7,8]. Quantitative SPECT/CT offers the possibility to continue and expand the potential of quantitative nuclear medicine applications [9,10]. Quantitative salivary gland SPECT/CT holds promise as an objective imaging modality for assessment of salivary dysfunction [11-13]. Furthermore, SUV using Q.Metrrix [14,15] and GI-BONE [16-19] software could be useful for the evaluation of jaw lesions. In recent years, Q.Volumetrix MI and GEniE-Xeleris 4 DR were developed. However, to the best of our knowledge, no reports have...
been published on SPECT/CT SUV of jaw lesions using Q.Volumetrix MI and GEniE-Xeleris 4 DR. The aim of this study was to investigate mandibular lesions with SPECT/CT using Q.Volumetrix MI and GEniE-Xeleris 4 DR.

**Material and methods**

**Subjects**

This prospective study was approved by the ethics committee of our university (ECNG-R-318). After providing written informed consent, 8 patients (2 men and 6 women; mean age 71.1 years [range 52-91 years]) with mandibular lesions (4 MRONJ, 3 chronic osteomyelitis, and 1 squamous cell carcinoma) underwent SPECT/CT at our university hospital from January 2020 to March 2021.

**SPECT/CT imaging**

SPECT/CT scans were obtained using a SPECT/CT scanner (Optima NM/CT 640, GE Healthcare, Tokyo, Japan), following our institutional protocol [14]. Patients were administered an intravenous injection of 740 MBq of technetium 99m hydroxymethylene diphosphonate (\(^{99m}\text{Tc-HMDP, Clear Bone Injectable, Nihon Medi-Physics, Tokyo, Japan}\) prior to the SPECT acquisition.

**Data analysis**

The maximum SUV was obtained by using software and a workstation (Q.Volumetrix MI and GEniE-Xeleris 4 DR, respectively, GE Healthcare, Tokyo, Japan). The localization and size of volume of interest (VOI) can be drawn over the lesion, mesial, distal, and opposite side as normal using the CT, SPECT, and SPECT/CT transaxials, coronals, and sagittals as the anatomical reference (Figure 1). Q.Volumetrix MI can analyse SUV of lesions by organ segmentation using optional pan and zoom imaging. Then, the dosimetry software provided multiple quantitative data for a given VOI. The maximum SUV in a given VOI was calculated as follows: maximum SUV = (maximum radioactivity/voxel volume)/(injected radioactivity/body weight).

**Statistical analysis**

Statistical analyses for the maximum SUV were performed by Mann-Whitney U test, using the statistical package IBM SPSS Statistics version 26 (IBM Japan, Tokyo, Japan). A p-value lower than 0.05 was considered as statistically significant.
Results

Table 1 shows 8 cases of SPECT/CT maximum SUV for mandibular lesions. Maximum SUVs for MRONJ ($n = 4, 25.4 \pm 4.9$), chronic osteomyelitis ($n = 3, 14.6 \pm 3.1$), and squamous cell carcinoma ($n = 1, 31.7$) were significantly higher than those of the opposite side as normal mandible ($3.8 \pm 0.7, 4.6 \pm 1.8$ and $7.4, p = 0.000$), respectively. Figures 2 and 3 indicate cases of chronic osteomyelitis (case 5) and squamous cell carcinoma (case 8), respectively.

Discussion

Despite SPECT/CT playing an important role in assessing oral and maxillofacial lesions [1-4], few reports have been published on SPECT/CT SUV of jaw lesions. In our study, SPECT/CT SUV using Q.Volumetrix MI showed potential as a useful parameter for the evaluation of mandibular lesions, such as detection and surgical planning.

Regarding comparison of utility with other molecular imaging applications, Q.Volumetrix MI is better than

Table 1. Cases of single-photon emission computed tomography (SPECT)/computed tomography (CT) maximum standardized uptake value for mandibular lesions

| Case | Age (years) | Gender | Lesion                  | Maximum standardized uptake value |
|------|-------------|--------|-------------------------|-----------------------------------|
|      |             |        | Lesion                  | Lesion   | Mesial | Distal | Normal |
| 1    | 80          | Woman  | MRONJ                   | 32.6     | 9.7    | 26.2   | 3.5     |
| 2    | 91          | Woman  | MRONJ                   | 24.8     | 16.5   | 15.9   | 3.3     |
| 3    | 72          | Woman  | MRONJ                   | 22.4     | 10.8   | 10.1   | 4.8     |
| 4    | 83          | Woman  | MRONJ                   | 21.9     | 20.8   | 14.9   | 3.8     |
| 5    | 69          | Man    | Chronic osteomyelitis   | 18.2     | 6.2    | 5.2    | 5.5     |
| 6    | 63          | Woman  | Chronic osteomyelitis   | 13.1     | 3.9    | 5.6    | 2.5     |
| 7    | 52          | Woman  | Chronic osteomyelitis   | 12.5     | 4.5    | 12.4   | 5.7     |
| 8    | 59          | Man    | Squamous cell carcinoma | 31.7     | 18.2   | 18.2   | 7.4     |

MRONJ – medication-related osteonecrosis of the jaw

Figure 2. Chronic osteomyelitis of the right side of the mandible in a 69-year-old man (case 5). Computed tomography (CT), single-photon emission computed tomography (SPECT), SPECT/CT, and maximum intensity projection (MIP) show a hot spot in the mandible. Maximum standardized uptake values (SUVs) of lesion (sky blue), mesial (red), distal (green), and normal (pink) were 18.20, 6.19, 5.24, and 5.51, respectively.
Q.Metrix \([14,15]\) at operability, because SUV analysis using Q.Volumetrix MI involves 1 step; however, Q.Metrix involves 2 steps (preparation for Q.Metrix and Q.Metrix). Furthermore, Q.Volumetrix MI is better than Q.Metrix regarding resolution, because Q.Volumetrix MI is a 512 matrix; however, Q.Metrix is a 256 matrix. Therefore, the localization and size of VOI can be drawn over the lesion, mesial, distal, and opposite side as normal using the CT, SPECT, and SPECT/CT transaxials, coronals, and sagittals as the anatomical reference by optional pan and zoom imaging. We consider that SUV using Q.Volumetrix MI software could be useful for the evaluation of jaw lesions.

Modabber et al. \([3]\) concluded that SPECT/CT can safely detect different kinds of inflammatory jaw pathologies compared to other conventional imaging modalities; additionally, SPECT/CT assists the surgeon in determining the expansion of the process preoperatively, thereby optimizing surgery planning. Miyashita et al. \([6]\) showed that the presence of regenerative vascularity with necrosis or inflammation seems to determine bone metabolism in MRONJ using 3-dimensional (3D) SPECT/CT. In this study, maximum SUVs for MRONJ \((n = 4, 25.4 \pm 4.9)\) and chronic osteomyelitis \((n = 3, 14.6 \pm 3.1)\) in mandible were higher than those of the opposite side as normal mandible \((3.8 \pm 0.7\) and \(4.6 \pm 1.8,\) respectively). Furthermore, Ogura et al. \([20]\) showed that surgical specimens from segmental mandibulectomy of MRONJ were analysed using cone-beam computed tomography (CBCT), and CBCT could be useful for the post-surgical evaluation of MRONJ. Miyashita et al. \([5]\) indicated that 3D SPECT/CT is useful not only for detecting jaw bone invasion of oral cancer but also for surgical planning. In this study, the maximum SUV for squamous cell carcinoma in mandible \((n = 1, 31.7)\) was higher than that of the opposite side as normal mandible \((7.4)\). Furthermore, Q.Volumetrix MI can analyse SUV of lesions by organ segmentation, such as the lesion, mesial, distal, and opposite side as normal, using optional pan and zoom imaging. We consider that SPECT/CT SUV using volumetric analysis showed potential as a useful parameter for evaluation of MRONJ and malignant tumour of the jaw, such as detecting, surgical planning, and post-surgical evaluation.

There were several limitations of this study. The sample was relatively small. Power calculation because of small sample sizes would strengthen the study, otherwise this is a significant limitation. Furthermore, we showed only maximum SUVs in this study, but there are other parameters concerning volumes and activities that should be utilized. Therefore, further research is necessary to validate these results.

**Conclusions**

This study evaluated mandibular lesions using Q.Volumetrix MI and GEniE-Xeleris 4 DR with SPECT/CT.
Volumetric analysis with SPECT/CT could be useful for the evaluation of mandibular lesions, such as detection and surgical planning.

Conflict of interest

The authors report no conflict of interest.

References

1. Suh MS, Lee WW, Kim YK, et al. Maximum standardized uptake value of 99mTc hydroxymethylene diphosphonate SPECT/CT for the evaluation of temporomandibular joint disorder. Radiology 2016; 280: 890-896.
2. Malina-Alfringer J, Klaeser B, Suter VGA, et al. Comparative evaluation of SPECT/CT and CBCT in patients with mandibular osteomyelitis and osteonecrosis. Clin Oral Investig 2019; 23: 4213-4222.
3. Modabber A, Schick D, Möhrlenrich SC, et al. Evaluation of SPECT/CT in the assessment of inflammatory jaw pathologies. Eur J Radiol 2020; 125: 108917.
4. Ogawa R, Ogura I. Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value. Dentomaxillofac Radiol 2021; 50: 20200516.
5. Miyashita H, Nakahara T, Asoda S, et al. Clinical value of 3D SPECT/CT imaging for assessing jaw bone invasion in oral cancer patients. J Craniofac Surg 2019; 47: 1139-1146.
6. Miyashita H, Kameyama K, Morita M, et al. Three-dimensional radiologic-pathologic correlation of medication-related osteonecrosis of the jaw using 3D bone SPECT/CT imaging. Dentomaxillofac Radiol 2019; 48: 20190208.
7. Torihara A, Daisaki H, Yamaguchi A, et al. Semiquantitative analysis using standardized uptake value in 123I-FP-CIT SPECT/CT. Clin Imaging 2018; 52: 57-61.
8. Huang K, Feng Y, Liu D, et al. Quantification evaluation of 99mTc-MDP concentration in the lumbar spine with SPECT/CT: compare with bone mineral density. Ann Nucl Med 2020; 34: 136-143.
9. Umeda T, Koizumi M, Fukai S, et al. Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. Ann Nucl Med 2018; 32: 105-113.
10. Dickson J, Ross J, Voö S. Quantitative SPECT: the time is now. EJNMMI Phys 2019; 6: 4.
11. Kim J, Lee H, Lee H, et al. Quantitative single-photon emission computed tomography/computed tomography for evaluation of salivary gland dysfunction in Sjögren’s syndrome patients. Nucl Med Mol Imaging 2018; 52: 368-376.
12. Ninomiya K, Toya S, Ogura I. Single-photon emission computed tomography/computed tomography for evaluation of salivary gland dysfunction: preliminary study on diagnostic ability of maximum standardized uptake value. Oral Radiol 2020; 36: 163-167.
13. Oohashi M, Toshima H, Hayama K, et al. Gallium-67 SPECT/CT for the evaluation of head and neck: preliminary study on maximum standardised uptake value in lesions, and in the parotid and submandibular glands. Pol J Radiol 2020; 85: e224-e229.
14. Ogura I, Sasaki Y, Sue M, et al. Tc-99m hydroxymethylene diphosphonate SPECT/CT for the evaluation of osteonecrosis of the jaw: preliminary study on diagnostic ability of maximum standardised uptake value. Clin Radiol 2020; 75: 46-50.
15. Toshima H, Ogura I. Assessment of inflammatory jaw pathologies using bone SPECT/CT maximum standardized uptake value. Dentomaxillofac Radiol 2020; 49: 20200043.
16. Ogura I, Kobayashi E, Nakahara K, et al. Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis. Ann Nucl Med 2019; 33: 776-782.
17. Okui T, Kobayashi Y, Tsuchimoto M, et al. Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging. Ann Nucl Med 2020; 34: 620-628.
18. Nakai F, Ohbayashi Y, Nakai Y, et al. Bone metabolism of the jaw in response to bisphosphonate: a quantitative analysis of bone scintigraphic images. Odontology 2020; 108: 653-660.
19. Minami Y, Ogura I. Bone single-photon emission computed tomography-C T peak standardized uptake value for chronic osteomyelitis, osteoradionecrosis and medication-related osteonecrosis of the jaw. J Med Imaging Radiat Oncol 2021; 65: 160-165.
20. Ogura I, Minami Y, Ono J, et al. CBCT imaging and histopathological characteristics of osteoradionecrosis and medication-related osteonecrosis of the jaw. Imaging Sci Dent 2021; 51: 73-80.